̶ Data From Narcolepsy Type 2 Cohort of ALKS 2680 Phase 1b Study to be Presented in Oral Presentation ̶ ̶ Data From Idiopathic Hypersomnia Cohort of ALKS 2680 Phase 1b Study Accepted for Poster Presentation ̶ DUBLIN , Sept. 23, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS ) today announced plans to present clinical data from its phase 1b study of ALKS 2680 in patients with narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) at the European Sleep Research Society's (ESRS) 27 th Congress, Sleep Europe 2024, taking place Sept. 24-27, 2024 in Seville, Spain .
ALKS 2680 is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy, a chronic, neurological disorder characterized by excessive daytime sleepiness. In an oral presentation and corresponding poster presentation, the company will share data from the cohort of patients with NT2 (n=9) from the phase 1b , proof-of-concept study evaluating single-dose, oral administration of ALKS 2680. Additionally, the company will present a poster with data from the cohort of patients with IH (n=8) from the same study.
As previously announced , ALKS 2680 was generally well tolerated with improved wakefulness compared to placebo in both cohorts. "Results from the ALKS 2680 phase 1b proof-of-concept study in patients with narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia highlight the potential of ALKS 2680 as a treatment option for pe.